Avacta has undertaken an innovative AI-driven analysis to assess differences in payload delivery between its proprietary pre|CISION peptide drug conjugate (PDC) platform and a market leading cleavable linker antibody drug conjugate (ADC). The aim was to assess published preclinical data for AstraZeneca/Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan, an exatecan derivative ADC), with preclinical data for Avacta’s exatecan PDC AVA6103 (FAP-EXd) in as comparable as way as possible. Enhertu, a class leading tumour-agnostic HER2-directed ADC used mainly for breast cancer, generated global FY25 revenue of $4.98bn. It is based on an exatecan derivative and uses a cathepsin-cleavable linker, while AVA6103 couples Avacta’s proprietary sustained release chemistry with a targeted release pre|CISION FAP-cleavable linker.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.